https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
160
POST-COVID-19 OSTEOPOROSIS: EMERGING CHALLENGES
AND THERAPEUTIC PERSPECTIVES
Kamoljonova Go
‘
zaloy Odiljon qizi
Abstract.
The COVID-19 pandemic, beyond its acute respiratory effects, has
led to a wave of long-term complications, including a notable increase in post-
infection osteoporosis. Recent studies suggest that SARS-CoV-2 disrupts bone
remodelling processes via immune dysregulation, cytokine storms, and prolonged
immobilization. Furthermore, corticosteroid therapy and reduced physical activity
during recovery exacerbate bone demineralization. This article explores the
pathophysiological mechanisms, clinical consequences, and therapeutic strategies
for managing post-COVID-19 osteoporosis. Understanding these interlinked
processes is vital for early intervention and preventing fractures in vulnerable
populations, especially the elderly and chronically ill. Timely diagnosis,
rehabilitation programs, and targeted pharmacological treatments could help
mitigate the burden of this emerging skeletal health crisis.
Key words.
COVID-19, osteoporosis, post-COVID syndrome, bone loss,
cytokine storm, corticosteroids, vitamin D deficiency, bone mineral density,
fracture risk, bone metabolism
Introduction.
The global health crisis caused by the novel coronavirus
disease (COVID-19) has left a lasting impact on multiple organ systems. While the
respiratory tract was primarily affected, it is now evident that the virus also exerts
long-term effects on the musculoskeletal system. Among these, osteoporosis
characterized by decreased bone density and increased fracture risk has emerged as
a growing concern in post-COVID-19 patients.
SARS-CoV-2 not only triggers acute systemic inflammation but also induces
a cascade of immune responses, hormonal imbalances, and prolonged inactivity,
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
161
all of which are known contributors to bone loss. In addition, many COVID-19
patients were treated with glucocorticoids, a well-documented risk factor for
secondary osteoporosis. This compounding of biological and treatment-related
factors has raised alarm within the medical community.
As countries transition into the post-pandemic phase, physicians are beginning
to observe an increase in osteoporotic changes and fragility fractures in patients
with a history of COVID-19. This highlights the need for a comprehensive
understanding of the underlying mechanisms, early diagnostic markers, and
prevention strategies to reduce long-term skeletal complications. This paper aims
to synthesize the latest scientific findings regarding post-COVID-19 osteoporosis
and propose evidence-based approaches to management.
Pathophysiological Mechanisms
.
The pathogenesis of post-COVID-19
osteoporosis is multifactorial, involving direct and indirect effects of SARS-CoV-
2 on bone metabolism. One major contributor is the cytokine stormóan exaggerated
inflammatory responseófrequently observed in severe COVID
-19 cases. Elevated
levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-?), and other pro-
inflammatory cytokines activate osteoclastogenesis, promoting bone resorption
while inhibiting osteoblast function.
Additionally, hypoxia caused by respiratory distress may impair osteocyte
viability, further disrupting bone homeostasis. Another important factor is vitamin
D deficiency, common among COVID-19 patients due to reduced sunlight
exposure, malnutrition, and altered metabolism during illness. Vitamin D plays a
critical role in calcium absorption and bone mineralization; its deficiency
exacerbates osteoporosis risk.
The widespread use of systemic corticosteroids to control inflammation in
moderate-to-severe COVID-19 cases significantly impacts bone density.
Corticosteroids accelerate bone turnover, reduce calcium absorption, and increase
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
162
urinary calcium loss. Immobilization during hospitalization or recovery also
contributes to disuse osteopenia, especially in elderly or critically ill patients.
Moreover, the ACE2 receptor, used by SARS-CoV-2 for cell entry, is
expressed in bone tissue. Viral interaction with ACE2 may disrupt the renin-
angiotensin-aldosterone system (RAAS), influencing bone remodeling processes.
These complex interactions underscore the need for targeted monitoring of skeletal
health in COVID-19 survivors
Epidemiology and Risk Factors
. While comprehensive global data is still
emerging, multiple observational studies have reported a rising trend in
osteoporotic fractures among individuals recovering from COVID-19, particularly
in older adults. According to recent European and Asian cohort studies, the
incidence of vertebral compression fractures and hip fractures has significantly
increased within 6ñ12 months following recovery from moderate
-to-severe
COVID-19.
•
Key risk factors for post-COVID-19 osteoporosis include:
•
Advanced age (>65 years)
•
Female sex, especially postmenopausal women
•
Prolonged hospitalization and ICU stay
•
High-dose corticosteroid therapy
•
Vitamin D deficiency
•
Sedentary lifestyle during recovery
•
Pre-existing chronic diseases (e.g., diabetes, hypertension, CKD)
Moreover, patients with multiple comorbidities are at a higher risk of
accelerated bone loss due to compounded inflammatory and metabolic stress.
These findings highlight the necessity for early screening and preventive measures
in high-risk populations.
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
163
Clinical Manifestations
. Post-COVID-19 osteoporosis may remain
asymptomatic in its early stages, often going undetected until the occurrence of
low-impact fractures. Common clinical features include:
•
Chronic lower back pain or bone pain
•
Loss of height over time
•
Kyphosis due to vertebral collapse
•
Fragility fractures, especially in the spine, hip, and wrist
In elderly or immunocompromised individuals, even minor falls may lead to
severe fractures, significantly impacting mobility and quality of life. Some patients
may experience delayed fracture healing, attributed to impaired bone regeneration
following systemic inflammation.
Diagnosis and Assessment
. Timely diagnosis of osteoporosis in post-COVID-
19 patients requires a combination of clinical evaluation and diagnostic imaging.
The standard method is Dual-Energy X-ray Absorptiometry (DEXA), which
measures bone mineral density (BMD). A T-
score of ? ñ2.
5 confirms osteoporosis.
Other useful assessments include:
•
Serum vitamin D levels
•
Parathyroid hormone (PTH)
•
Calcium and phosphate levels
•
Bone turnover markers (e.g., CTX, P1NP)
In patients with recent COVID-19, these parameters should be monitored
during follow-up visits, especially if corticosteroid use or immobilization occurred.
Spinal X-rays are also recommended in cases of unexplained back pain.
Conclusion
. The long-term skeletal consequences of COVID-19, particularly
the emergence of secondary osteoporosis, demand urgent attention in clinical
practice. As evidence continues to accumulate, it becomes increasingly clear that
bone health must be prioritized in the post-pandemic healthcare landscape. Early
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
164
diagnosis, patient education, and individualized treatment can significantly reduce
morbidity associated with osteoporotic fractures.
Healthcare providers must incorporate bone density screening and preventive
care into COVID-19 recovery protocols, especially for vulnerable groups. A
multidisciplinary approach involving internists, endocrinologists, physiotherapists,
and nutritionists is essential for optimal outcomes.
References:
1. Orwoll, E. S., & O'Neill, T. W. (2021). The impact of COVID-19 on bone
health. Journal of Bone and Mineral Research, 36(9), 1622ñ1629.
2. Di Filippo, L., et al. (2020). COVID-19 and the risk of bone loss: What do
we know? Endocrine, 69(2), 229ñ232.
3. Cummings, S. R., & Melton, L. J. (2021). Osteoporosis in the time of
COVID-
19. The Lancet Diabetes & Endocrinology, 9(9), 561ñ562.
4. Wang, J., et al. (2022). Corticosteroid-induced osteoporosis in COVID-19
patients: A retrospective study. Osteoporosis International, 33(3), 589ñ596.
5. Holick, M. F. (2020). Vitamin D and immune function during the
COVID-19 pandemic. Nutrients, 12(9), 2769
